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Chronic kidney disease (CKD) has long been identiﬁed
as a risk factor for patients undergoing surgical aortic
valve replacement (SAVR). This is relevant not only to the
perioperative period, for which it predicts 30-day mor-
tality, but also to the longer-term prognosis. Data from the
Society of Thoracic Surgeons database, including more
than 145,000 patients who underwent SAVR with or
without concomitant coronary bypass grafting, demon-
strate that patients with CKD had a 50% reduction in
median survival over a period of 15 years (1). In addition,See page 869acute kidney injury (AKI) after SAVR, even if patients
recover from the acute event, predicts poor outcomes in
the long term. For octogenarians who undergo isolated
SAVR, survival decreases from 6.4 years without AKI to
3.4 years with AKI and down to only 0.7 years median
survival if patients needed dialysis during the perioperative
course (1).
Transcatheter aortic valve implantation (TAVI) has been
identiﬁed as an alternative treatment option in patients who
are at high risk or unsuitable for SAVR (2,3). The improved
outcomes in these patients are seen as a result of the
reduction of surgical trauma and inﬂammatory response, as
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these potential advantages change the post-TAVI risks of
patients with speciﬁc comorbidities such as CKD.
In this issue of the Journal, Yamamoto et al. (4) present
the outcomes of 642 consecutive patients treated with TAVI
at their institution. Patients were divided into 4 groups
according to the degree of CKD, determined using their
estimated glomerular ﬁltration rate (eGFR) before TAVI,
while patients on dialysis were excluded. Patients with severe
CKD presented with lower body mass indexes and body
surface areas but had signiﬁcantly higher logistic European
System for Cardiac Operative Risk Evaluation and Society
of Thoracic Surgeons scores. The investigators found that
patients with CKD grade 4 (eGFR <30 ml/min/1.73 m2)
had higher 30-day mortality and that the presence of CKD
grades 4 and 3b (eGFR <45 ml/min/1.73 m2) predicted
higher mortality 1 year after the procedure. Indeed, CKD
grades 4 and 3b, in addition to the logistic European System
for Cardiac Operative Risk Evaluation score, were found to
be the only independent predictors of 1-year mortality after
TAVI.
In 2 recently published reports on this subject, investi-
gators were unable to identify severe CKD (according to
eGFR) as an independent predictor of mortality after TAVI
(5,6). However, given data from registries on the predictive
value of the serum creatinine (7,8) and the fact that this new
analysis was performed on a larger number of patients and
with a more sophisticated subdivision of CKD grades, the
results are not surprising from the clinical point of view.
With the results from SAVR in mind, it would have been
interesting had Yamamoto et al. (4) analyzed the prognosis
of patients without CKD who undergo TAVI and experi-
ence post-interventional AKI (in this study, nearly 15%),
but this was not the focus of their study. In addition, it
would have been favorable had the investigators provided
more procedural information, such as the duration of
rapid pacing, pre-dilation of the native aortic valve, as well
as intraoperative hypotension and perioperative use of
inotropic support, all known as potential risk factors for
post-TAVI AKI.
Nevertheless, the questions remain as to what kinds of
complications patients with CKD experience directly after
TAVI as well as their ﬁnal causes of death early and 1 year
after the procedure. In this context, it is quite surprising to
read that for patients with CKD grade 4 in this investiga-
tion, the need for acute dialysis after the initial TAVI
procedure was quite low at only 4.9%. This is in contrast to
previously published reports on TAVI, in which the need
for dialysis in the total cohort, including the small group of
patients with CKD grade 4 but also all other patients with
mild or no pre-TAVI CKD, has been reported at 3% to
9.3% (3,9,10). In addition, although the incidence of dialysis
in patients with CKD grade 4 was the highest, the differ-
ence from the other 3 groups did not reach statistical
signiﬁcance, but this may be a result of small patient
numbers.
JACC Vol. 62, No. 10, 2013 Wendler and MacCarthy
September 3, 2013:878–80 Renal Failure Post-TAVI
879This raises 2 questions. First, do Yamamoto et al. (4)
use a particularly effective medical management strategy
to prevent AKI? Second, if severe AKI is not the cause of
death in patients with CKD, why do they do badly in
terms of survival? The ﬁrst question has been answered
by the investigators, as they mention that they only used
pre-hydration begun 12 h before the procedure. They
also endeavored to reduce the volume of radiopaque
contrast used during TAVI to prevent AKI in patients
with severe CKD, although the volumes of contrast do
not differ from those used in other studies. The second
question is left more open, as the investigators unfortu-
nately do not provide speciﬁc data on the causes of death
of their patients. From the Edwards SAPIEN Aortic
Bioprosthesis European Outcome registry (8), it is well
known that CKD is among the strongest independent
predictors of 1-year mortality. Among noncardiac causes
of death after TAVI, the incidence of death from renal
failure is 12.5%, the second most commonly observed
behind pulmonary diseases (23.8%) (8). But in the context
of the investigation by Yamamoto et al. (4), it may be of
interest that patients with CKD grades 3b and 4 showed
a trend toward increased stroke risk, with 4.4% and 8.2%
of strokes reported.
These ﬁndings raise the question of whether patients with
CKD are at higher risk for post-operative complications as
a result of other comorbidities, such as small vessel disease
affecting their cerebral, myocardial, and general perfusion
and function, or malnutrition and frailty. Is CKD merely
a surrogate marker for more widespread and advanced
macrovascular and microvascular disease? The individual
baseline characteristics seem to indicate that the groups are
quite comparable in this respect, but the logistic European
System for Cardiac Operative Risk Evaluation and Society
of Thoracic Surgeons scores are higher in patients with se-
vere CKD, which is not explained by the concomitant kidney
disease itself. The answers to these questions are not fully
known, and it is therefore obvious that we need more so-
phisticated data on these kinds of patient cohorts (including
data on frailty or discrimination of coexistent coronary dis-
ease) to identify their differences.
In patients with severe CKD, concomitant pre-existing
small vessel disease may play a particular role in this
respect. As cardiac function has been found to be
impaired early after TAVI (11), small vessel disease in
these patients may increase the risk for organ malperfu-
sion. Although this may not always result in serious easily
identiﬁable events such as strokes, myocardial infarcts, or
dialysis, which are currently counted as serious compli-
cations in TAVI studies, organ malperfusion may result in
moderate organ dysfunction and increased inﬂammatory
response. This, in combination, may increase perioper-
ative stress and prolong recovery and mobilization, which,
particularly in this elderly group of patients, will cause
additional complications.To ﬁnd answers to these questions, it is of vital
importance that we get more “organ-speciﬁc” information
on the various effects of TAVI and identify periprocedural
changes that may contribute to the renal insult. Although
it was sufﬁcient during the early TAVI experience to focus
on clinical outcomes, it is now time to get a better
understanding of the speciﬁc (and perhaps more subtle)
side effects of the procedure. In this respect, it is of vital
importance to understand how cardiac function is directly
affected by the procedure. What happens during and
immediately after the procedure in terms of not only
inﬂammatory response, organ malperfusion, and cerebral
but also renal artery embolization, and how do these
phenomena predict perioperative complications? Fortu-
nately, we have tools such as real-time hemodynamic
monitoring and sensitive biomarkers available to perform
sophisticated investigations to obtain this vital information.
During the early years, we (as “heart teams” of interven-
tional cardiologists and surgeons) developed the technical
principals of TAVI while device technology rapidly
advanced in parallel. This resulted in a reliable and
reproducible technique with high procedural success rates.
In the next phase of evolution of TAVI, we need to obtain
more detailed information on the side effects of TAVI to
fully understand what predicts outcomes in speciﬁc groups
of patients such as those with CKD. This will improve our
patient selection and enable us to tailor interventional and
surgical treatment to individual patients, ultimately
improving the outcome of this exciting new treatment
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